Takeda announced that the U.S. Food and Drug Administration FDA has approved EOHILIA or budesonide oral suspension , the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis EoE .1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February. EOHILIA is a corticosteroid indicated for 12 weeks of treatment in patients 11 years and older with EoE.1 Developed specifically for EoE, EOHILIA’s novel formulation of budesonide confers thixotropic properties – flowing more freely when shaken and returning to a more viscous state when swallowed. “Various formulations of corticosteroids have been used in the past to manage EoE, but in an off-label capacity and using multiple delivery options. With EOHILIA, it’s gratifying to now have an FDA-approved treatment specifically formulated for a consistent dose delivery with demonstrated ability to address esophageal inflammation and EoE dysphagia symptoms,” said Ikuo Hirano, MD, professor of medicine and director of the Kenneth C. Griffin Esophageal Center in the Division of Gastroenterology and Hepatology at Northwestern University Feinberg School of Medicine. “As the treatment needs and goals of patients with EoE can vary, I welcome the flexibility that EOHILIA offers as an oral medication.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TAK:
- Takeda to rapidly initiate the first global Phase 3 trials of TAK-861
- Takeda announces CFO Costa Saroukos to leave, Milano Furuta to succeed
- Protagonist Therapeutics, Takeda enter into license agreement for Rusfertide
- Is TAK a Buy, Before Earnings?
- Halozyme announces Takeda received EC approval for HYQVIA